Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-OSA master protocol of once-daily orforglipron in obstructive sleep apnea with overweight or obesity
2024-515905-25-00Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in obstructive sleep apnea hypopnea syndrome (OSAHS), Overweight and obesity comparing Orforglipron with Placebo (2 arms). Primary endpoint: Change from baseline in apnea-hypopnea index. Started Jan 2025; status: completed.
02
Drugs
orforglipron
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)Overweightobesity
Beyond the preview
Go deeper on 2024-515905-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515905-25-00.